CymitQuimica logo

CAS 1353550-13-6

:

Olmutinib

Description:
Olmutinib is a small molecule inhibitor primarily designed for the treatment of non-small cell lung cancer (NSCLC) with specific mutations in the epidermal growth factor receptor (EGFR). It is classified as a tyrosine kinase inhibitor (TKI), targeting the ATP-binding site of the EGFR, thereby blocking its activity and inhibiting downstream signaling pathways that promote tumor growth and survival. The compound exhibits selectivity for both wild-type and mutant forms of EGFR, making it a valuable therapeutic option for patients with certain genetic profiles. Olmutinib is administered orally and has been studied for its efficacy and safety in clinical trials. Its pharmacokinetic properties include a favorable absorption profile, with metabolism primarily occurring in the liver. Common side effects may include skin rash, diarrhea, and fatigue, which are typical of many EGFR inhibitors. Overall, Olmutinib represents a targeted approach in oncology, aiming to improve outcomes for patients with EGFR-driven malignancies.
Formula:C26H26N6O2S
InChI:InChI=1S/C26H26N6O2S/c1-3-23(33)27-19-5-4-6-21(17-19)34-25-24-22(11-16-35-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
InChI key:InChIKey=FDMQDKQUTRLUBU-UHFFFAOYSA-N
SMILES:O(C1=C2C(=NC(NC3=CC=C(C=C3)N4CCN(C)CC4)=N1)C=CS2)C5=CC(NC(C=C)=O)=CC=C5
Synonyms:
  • N-[3-[[2-[[4-(4-Methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-2-propenamide
  • 2-Propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-
  • HM 61713
  • Olmutinib
  • BI 1482694
Found 5 products.